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ABSTRACT
Mutations in the ALK  tyrosine kinase receptor gene represent important 
therapeutic targets in neuroblastoma, yet their clinical translation has been 
challenging. The ALKF1174L mutation is sensitive to the ALK inhibitor crizotinib only at 
high doses and mediates acquired resistance to crizotinib in ALK-translocated cancers. 
We have shown that the combination of crizotinib and an inhibitor of downstream 
signaling induces a favorable response in transgenic mice bearing ALKF1174L/MYCN-
positive neuroblastoma. Here, we investigated the molecular basis of this effect and 
assessed whether a similar strategy would be effective in ALK-mutated tumors lacking 
MYCN overexpression. We show that in ALK-mutated, MYCN-amplified neuroblastoma 
cells, crizotinib alone does not affect mTORC1 activity as indicated by persistent 
RPS6 phosphorylation. Combined treatment with crizotinib and an ATP-competitive 
mTOR inhibitor abrogated RPS6 phosphorylation, leading to reduced tumor growth 
and prolonged survival in ALKF1174L/MYCN-positive models compared to single agent 
treatment. By contrast, this combination, while inducing mTORC1 downregulation, 
caused reciprocal upregulation of PI3K activity in ALK-mutated cells expressing wild-
type MYCN. Here, an inhibitor with potency against both mTOR and PI3K was more 
effective in promoting cytotoxicity when combined with crizotinib. Our findings should 
enable a more precise selection of molecularly targeted agents for patients with ALK-
mutated tumors.
INTRODUCTION 
The discovery of activating mutations in the ALK 
gene in high-risk neuroblastoma (NB) has opened new 
opportunities for the development of novel therapeutic 
strategies against this often-fatal childhood cancer of the 
sympathetic nervous system [1]. Tumor cells expressing 
ALK mutations depend on this oncogene for their survival 
and are typically sensitive to ALK inhibitors such as 
TAE684 [2, 3]. Crizotinib - the only ALK inhibitor with Oncotarget 8738 www.impactjournals.com/oncotarget
FDA approval - has limited activity against the various 
ALK mutations identified in patients with NB [4]. Indeed, 
in a Children’s Oncology Group (COG) trial, only 1 of 
11 patients with ALK-mutated NB had an objective 
response to this agent [4]. When tested against NB cells 
bearing either of the two more common mutations, 
crizotinib inhibited growth and induced apoptosis in cells 
expressing ALKR1275Q but failed to inhibit the growth of 
ALKF1174L-positive cells [5, 6]. Similarly, in the COG trial, 
3 of the 4 patients with ALKF1174L–positive NB tumors 
developed progressive disease, compared with 2 of 5 
whose tumors had a missense mutation at the R1275 locus 
[4]. This relative resistance of ALKF1174L to crizotinib has 
been attributed to the increased ATP-binding affinity of the 
mutant, with complete inhibition of constitutively active 
ALK attainable only at very high doses of the drug [5]. 
ALKF1174L is thus considered the most aggressive of all ALK 
mutations in NB, possessing higher transforming potential 
and segregating with MYCN  oncogene  amplification, 
itself a marker of aggressive disease in high-risk NB 
[7].  Importantly,  ALKF1174L also arises secondarily as 
a mechanism of resistance after an initial response to 
crizotinib in patients with ALK-rearranged cancers [8]. 
Although several other compounds are in 
development or in early-phase trials [9], there is no 
certainty that these compounds will be any more potent 
than crizotinib against mutant ALK. Therefore, novel 
strategies  that  increase  the  efficacy  of  crizotinib  in 
ALK-mutated NB, without resorting to doses that could 
cause irreversible toxicity in children, are particularly 
relevant. One promising strategy has been the combined 
use of agents that target not only aberrant ALK, but also 
other signaling nodes whose activation by mutant ALK 
contributes to the malignant phenotype [10]. Based 
on activation of the PI3K/mTOR pathway in a murine 
transgenic NB model expressing ALKF1174L and MYCN, 
we demonstrated that combining an ATP-competitive 
mTOR inhibitor with crizotinib induced tumor regression, 
although the molecular basis for this result was unclear at 
the time [6]. 
The mTOR protein kinase is selectively activated 
in anaplastic large cell and T-cell lymphomas that are 
positive for the NPM-ALK chromosomal translocation 
[11]; however, its role in NB cells expressing the full-
length  mutated ALK  receptor  remains  to  be  defined. 
mTOR signaling occurs in the context of at least two 
multiprotein complexes, mTORC1 and mTORC2, that 
are key components of the PI3K/AKT network and are 
activated by growth factors and metabolic status. The 
mTORC1 complex is a critical mediator of cell growth 
and metabolism and regulates cell size and protein 
synthesis through its substrates p70S6K and 4E-BP1 
[12]. Activated  p70S6K  phosphorylates  RPS6,  an  S6 
protein of the 40S ribosomal subunit, which in turn 
causes feedback inhibition of insulin-like growth factor 
1 (IGF-1) signaling by phosphorylating insulin receptor 
substrate 1 (IRS-1), leading to its degradation [13, 14]. 
The mTORC2 complex, which is also activated by growth 
factor stimulation, regulates cell proliferation and survival 
through direct phosphorylation of AKT on serine 473 [12].
Here, we sought to dissect the critical components 
of ALKF1174L-associated signaling in the presence of MYCN 
overexpression to identify the molecular determinants of 
the  favorable  response  to  combined  crizotinib/mTOR 
inhibitor therapy previously demonstrated using the TH-
ALKF1174L/MYCN transgenic model [6]. Moreover, we 
investigated whether this combination would be just as 
effective in ALK-mutated NB models in the absence of 
MYCN amplification. We show that in cells overexpressing 
both ALKF1174L and MYCN, there is persistent activation 
of  mTORC1  in  the  context  of  single-agent  crizotinib 
treatment. Thus, targeting mTORC1 in combination with 
ALK leads to enhanced antitumor efficacy and prolongs 
survival in mouse xenograft models of human NB 
coexpressing ALKF1174L and MYCN. By contrast, in cells 
without MYCN amplification, this combination, although 
inducing downregulation of mTORC1, led to reciprocal 
upregulation  of  PI3K  activity  not  only  in  ALKF1174L-
mutated cells but also in those that express the more 
common ALKR1275Q-mutation. In this instance, an inhibitor 
with equal potency against mTOR and PI3K was more 
effective in promoting cytotoxicity when combined with 
crizotinib. Our results provide a molecular rationale for 
the selection of targeted agents to prevent or delay the 
onset of resistance in patients with ALK-mutated NB.
RESULTS 
PI3K/AKT but not mTOR is inhibited by 
crizotinib in ALKF1174L/MYCN-positive NB cells
To probe the signaling networks in crizotinib-treated 
NB cells harboring the ALKF1174L mutation and amplified 
MYCN, we exposed Kelly NB cells (which express both 
genes) to crizotinib or vehicle for 6 hours and analyzed 
their gene expression profiles. High doses of crizotinib 
were required to downregulate phosphorylation of ALK 
at Y1604 (Fig. 1A). Using comparative marker selection 
methods and gene set enrichment analysis (GSEA), we 
identified a number of significantly enriched gene sets in 
crizotinib-treated cells whose transcripts were functionally 
linked to protein kinase, insulin receptor, mTOR signaling, 
MYC, E2F and PTEN pathways. Surprisingly however, the 
majority of the PI3K/mTOR pathway transcripts were not 
uniformly downregulated in the crizotinib-treated cells, 
suggesting inadequate suppression of the pathway by 
crizotinib even at high doses (Supplementary Table 1).
To  determine  whether  these  findings  extend  to 
the protein level, we treated Kelly cells with doses of 
crizotinib similar to those used for the expression analysis Oncotarget 8739 www.impactjournals.com/oncotarget
and  analyzed  the  three  main  targets  of  both  mTOR 
and PI3K signaling: pRPS6 and p4E-BP1, markers of 
mTORC1 activation, as well as phosphorylation of AKT 
at serine 473 and threonine 308, markers of mTORC2 and 
PI3K activation, respectively. We observed that relatively 
high doses of crizotinib for 6 hours were associated with 
a decrease in phosphorylation of AKTT308 and AKTS473 
(Fig. 1B). However, pRPS6 was unaffected and p4E-BP1 
was even upregulated on exposure to crizotinib (Fig. 1B). 
Thus, in MYCN-amplified NB cells expressing ALKF1174L, 
crizotinib effectively downregulated mTORC2 and PI3K, 
but had no appreciable inhibitory effect on mTORC1 
activity.
We next asked whether these differential 
downstream signaling changes also occur with genetic 
depletion of mutated ALK. Abrogation of ALK expression 
by stable shRNA transduction led to decreases in pAKT 
at S473 and T308 but not pRPS6 in Kelly cells. The 
same phenomenon was observed in MYCN-amplified 
NGP cells that express non-mutated, non-amplified but 
phosphorylated ALK (Fig. 1C). Together, these studies 
indicate that in MYCN-amplified  NB  cells,  efficient 
depletion of activated ALK causes differential effects 
on  downstream  signaling:  PI3K  and  mTORC2  are   
downregulated, while mTORC1 activity is maintained.
MYCN  amplification  determines  downstream 
signaling responses to crizotinib in ALK-mutated 
cells 
The above results suggested that deregulated 
MYCN could contribute to the sustained upregulation 
of mTORC1 activity in NB cells expressing activated 
ALK. To test this hypothesis, we abolished the expression 
of MYCN in MYCN-amplified,  ALKF1174L-expressing 
Kelly cells using shRNA knockdown, and tested whether 
mTORC1 substrates pRPS6 and p4E-BP1 were affected. 
Partial knockdown of MYCN that still maintained cell 
viability did not lead to appreciable changes in pRPS6 
levels. However, the phosphorylation of 4E-BP1 at 
residues associated with mTORC1-mediated inhibition 
(T37/46) [15] were downregulated at the level of MYCN 
knockdown achieved (Fig. 2A). Moreover, we observed 
upregulation of pAKT upon MYCN knockdown (Fig. 2A), 
consistent with a loss of feedback inhibition associated 
with  reduced  mTORC1  activity.  To  inhibit  MYCN 
expression completely and to further clarify the extent to 
which it contributes to mTORC1 activity in the presence 
of mutated ALK, we overexpressed ALKF1174L in the 
SHEP NB cell line, which stably expresses a tetracycline-
repressible  MYCN construct (Fig. 2B). Addition of 
doxycycline to ALKF1174L-positive SHEP cells led to 
depletion of MYCN expression, which was associated 
with a significant decrease in pRPS6 levels compared 
with cells in which MYCN was expressed (Fig. 2B). 
Interestingly, we also noted that pRPS6 expression was 
decreased in GFP-expressing SHEP cells when MYCN 
was repressed (Fig. 2B). These data suggest that MYCN 
contributes to mTORC1 activation.
We next explored the effects of MYCN 
overexpression in ALKF1174L-positive cells upon exposure 
to crizotinib. As noted previously, we again observed a 
decrease in pRPS6 levels in DMSO-treated cells when 
MYCN expression was shut off by the addition of 
doxycycline  (Doxycycline  +)  (Fig.  2C).  Inhibition  of 
Figure 1: ALK inhibition does not affect mTORC1 signaling in MYCN-amplified ALKF1174L-mutant human NB cells. 
A, Western blot analysis of pALKY1604 in ALKF1174L-expressing Kelly NB cells treated with increasing concentrations of crizotinib for 6 hr. 
B, Western blot analyses of the indicated downstream signaling proteins in Kelly cells after treatment with increasing concentrations of 
crizotinib for 6 hr. C, Western blot analyses in Kelly (ALKF1174L) and NGP (ALK-wild type) cells of the indicated signaling proteins in cells 
in which ALK expression was depleted by shRNA knockdown. Oncotarget 8740 www.impactjournals.com/oncotarget
MYCN expression in both GFP and ALKF1174L-positive 
SHEP cells led to a decrease in RPS6 phosphorylation 
compared with results in MYCN-overexpressing cells 
(p<0.05;  Fig.  2C).  Crizotinib  also  led  to  significant 
downregulation of pAKTS473 levels in MYCN 
overexpressing cells (Fig. 2C), but not in cells in which 
MYCN expression was repressed (Doxycycline +), where 
pAKTS473 levels remained elevated. Similarly, MYCN 
repression led to elevation of pAKTT308 (hence PI3K) in 
SHEP cells, which was further increased on exposure 
to crizotinib, consistent with continued loss of RPS6-
mediated feedback inhibition (Fig. 2C). Thus, in ALKF1174L 
cells without MYCN overexpression, crizotinib eventually 
induced downregulation of mTORC1, with both mTORC2 
and PI3K remaining activated. In contrast, induction of 
MYCN expression led to downregulation of mTORC2, 
while sustaining persistent activation of mTORC1. These 
findings  demonstrate  that  amplified  MYCN maintains 
mTORC1 activity in NB cells and contributes to a varied 
response in AKT activity following crizotinib treatment.
A selective mTOR inhibitor enhances the effect 
of crizotinib in MYCN-amplified  ALKF1174L-
expressing NB cells 
The  above  findings  suggest  that  continued  or 
compensatory upregulation of key signaling molecules 
during crizotinib treatment could contribute to the limited 
activity of this agent against NB cells expressing ALKF1174L 
with concomitant overexpression of MYCN. To address 
this issue, we screened several mTOR, PI3K and dual 
PI3K/mTOR pathway inhibitors in NB cells (Table S2), 
identifying Torin1 [16] and Torin2 [17] as promising 
candidates. Although Torin1, an ATP-competitive mTOR 
inhibitor [16] with preferential activity against mTOR 
(EC50, 3 nM) compared to PI3K (EC50, 1.8 µM), exhibited 
impressive cytotoxicity with downregulation of mTORC1 
and mTORC2 targets in Kelly NB cells (Supplementary 
Fig. S1A and B), it has a low-yielding synthetic route, 
poor water solubility, limited oral bioavailability and a 
short half-life. These restrictions led us to test a second-
generation analogue, Torin2 [17], which proved more 
potent than Torin1 against mTOR (EC50, 0.25 nM) as well 
as PI3K (EC50, 200 nM), and led to a decrease in both 
pAKTS473 and pRPS6 levels (Supplementary Fig. S1C). 
Because of its reported lack of sustained cytotoxic activity 
as a single agent [17], we next asked whether Torin2 
would enhance the sensitivity of ALKF1174L-expressing NB 
cells to crizotinib. Indeed, the combination of Torin2 and 
crizotinib reduced the viability of both Kelly and LAN-
1 (ALKF1174L-positive/MYCN amplified) cells beyond that 
achieved by either single agent alone (Fig. 3A). Growth 
inhibition in Kelly cells was accompanied by a G0-G1 cell 
cycle arrest (Fig. 3B), although a significant increase in 
apoptosis was not observed (Supplementary Fig. S2A and 
S2B). 
Further testing of this combination in both Kelly 
and LAN-1 cell lines using synergistic doses of each 
compound elicited a striking and sustained decrease in 
phosphorylated RPS6 and 4E-BP1 as well as AKTS473, 
confirming the targeted inhibition of the mTORC1 and 
mTORC2 complexes (Fig. 3C). Torin2 as a single agent 
Figure 2: MYCN sustains mTORC1 signaling in NB cells. A, Western blot analyses of the indicated signaling proteins in Kelly 
cells in which MYCN expression was suppressed using shRNA knockdown. B, Composite of western blot analyses of the indicated proteins 
in SHEP NB cells expressing a doxycycline-repressible MYCN construct in which ALKF1174L was overexpressed using retroviral transduction. 
Controls are SHEP cells transduced with GFP. Doxycycline (1 µg/ml) was added for 24 hr. to repress MYCN expression. Repression of 
MYCN led to a 32% reduction in pRPS6 levels compared to cells expressing MYCN (P = 0.017) as measured by densitometry. C, Western 
blot analyses of the indicated proteins in SHEP cells expressing ALKF1174L with (+) or without (-) MYCN repression treated with 1 µM 
crizotinib for the indicated duration. Oncotarget 8741 www.impactjournals.com/oncotarget
caused  an  increase  in  the  marker  of  PI3K  activation, 
pAKTT308, suggesting loss of feedback inhibition by 
mTORC1.  However,  the  combination  of  Torin2  and 
crizotinib led to downregulation of pAKTT308 in both 
cell lines (Fig. 3C). Together, these results show that 
an mTOR-specific inhibitor can augment the cytotoxic 
activity of crizotinib in ALKF1174L-mutated NB cells with 
MYCN amplification.
The combination of crizotinib and Torin2 shows 
enhanced antitumor activity and prolongs 
survival in a xenograft model of human ALKF1174L/
MYCN –amplified NB
Following the positive results obtained from 
the combination of crizotinib and Torin2 treatment in 
the transgenic NB model [6], we sought to determine 
whether similar results would be observed in models of 
human disease. Therefore, we tested the crizotinib/Torin2 
combination in human NB xenograft models generated 
by subcutaneous injection of Kelly cells into NSG mice. 
When tumors reached an optimal size (tumor volume, 
~60mm3), the mice were separated into four groups (n = 8 
each) and treated orally once daily with vehicle, crizotinib 
(75 mg/kg), Torin2 (20 mg/kg), or a combination of the 
two. Mice were treated in “cycles”, each consisting of 
5 days on and 5 days off treatment for a total of three 
cycles, to mimic clinical use of these drugs as closely as 
possible. Crizotinib by itself lacked any apparent activity, 
while Torin2 significantly suppressed tumor growth at 
18 days (Fig. 4A), although this result did not translate 
to prolonged survival (Fig. 4B). Combination treatment, 
by contrast, significantly attenuated tumor growth and 
Figure 3: Torin2, a selective mTORC1 inhibitor, enhances the effect of crizotinib in ALKF1174L-positive, MYCN-amplified 
NB cells. A, Survival analysis of ALKF1174L-positive, MYCN-amplified Kelly (upper) and LAN-1 (lower) cells treated for 3 days with 
increasing concentrations of crizotinib (X-axis), Torin2 (1 nM to 1 µM), or the combination at the indicated ratios (crizotinib:Torin2). B, 
Cell cycle analysis of crizotinib and Torin2 in Kelly cells. Cells were treated for 72 hr. with vehicle (DMSO), crizotinib (C), Torin2 (T2) or 
both (C+T2), and analyzed by flow cytometry. The results of three separate experiments are reported as mean ± SEM percentages of cells 
in each phase of the cell cycle (**P<0.01; Student’s unpaired t-test). C, Western blot analysis of the indicated proteins in Kelly (left) and 
LAN-1 (right) cells exposed to crizotinib, Torin2, or the combination. Concentrations of the two agents used together: crizotinib, 1 µM; 
Torin2, 100 nM. Oncotarget 8742 www.impactjournals.com/oncotarget
decreased tumor volumes, with minimal toxicity and 
prolonged survival compared to control animals and 
cohorts treated with either Torin2 or crizotinib alone (Fig. 
4B).
To account for the enhanced activity of crizotinib 
plus  Torin2  in  terms  of  changes  in  specific  signaling 
molecules, we analyzed post-treatment samples from 
the subcutaneous xenograft models of ALKF1174L-mutated 
NB (n = 3 specimens per group, collected when tumors 
reached the volume threshold: range, 19-27 days; mean 21 
days). Morphological analysis of tumors treated with the 
combination showed massive hemorrhage and necrosis, in 
contrast to the negligible or only minor changes in cellular 
architecture seen with use of either agent alone (Fig. 
Figure 4: Combination of crizotinib and Torin2 leads to tumor regression and extends survival in an ALKF1174L/MYCN- 
overexpressing human NB cell xenograft model with attendant effects on downstream signaling. A, The growth of 
Kelly cell tumor xenografts was monitored in mice treated with vehicle, crizotinib, Torin2 or the combination, orally once daily for 3 
cycles. Tumor volume measurements were truncated at the time point at which the first animal in a cohort had a tumor volume measuring 
>1000mm3. Tumor volumes are expressed as mean ± SEM. Volume comparisons were performed at day 18 (vehicle vs. crizotinib, P=not 
significant; vehicle vs. Torin2, *P<0.01; vehicle vs. combination, **P< 0.001; all comparisons by two-way ANOVA). B, Kaplan-Meier 
survival analysis of mice treated with control, single agents alone or the combination of crizotinib and Torin2 (crizotinib vs. combination, 
*P=0.03; Torin2 vs. combination, **P=0.005; all by log-rank test). C, Hematoxylin and eosin (H&E), pRPS6 and cleaved caspase-3 
immunohistochemical staining on tumor sections following treatment with either single agents or the combination. The scale bar represents 
50 µm. D, Immunoblot analysis of the indicated proteins in tumors of mice treated as indicated above. E, Bioluminescence measurements 
of human NB xenograft models established by intravenous injection of ALKF1174L/MYCN-positive NB cells. Animals were treated with the 
indicated agents. F, Kaplan-Meier survival analysis of mouse xenograft models of human NB treated with the indicated agents (crizotinib 
vs. combination, **P=0.001; by log rank test).Oncotarget 8743 www.impactjournals.com/oncotarget
4C). This paucity of morphologic alterations correlated 
with a lack of effect of crizotinib on pALK and on the 
expression  of  either  mTORC1  (pRPS6  and  p4E-BP1) 
or mTORC2 (pAKTS473) targets (Fig. 4D). In fact, on 
immunohistochemical (IHC) staining, pRPS6 appeared 
to be upregulated in the crizotinib-treated tumors (Fig. 
4C). The profile of molecular events seen with single-
agent therapy contrasted sharply with that induced by 
the crizotinib/Torin2 combination. Indeed, there was a 
striking decrease in AKTS473 phosphorylation as well as the 
virtual disappearance of pRPS6 and p4E-BP1 on western 
analysis of treated tumor cells (Fig. 4D). This dramatic 
decrease in mTORC1 signaling was confirmed by IHC 
showing downregulation of pRPS6 (Fig. 4C). Moreover, 
the combination also led to an increase in tumor cell death 
by H&E and cleaved caspase-3 staining, compared with 
either agent alone (Fig. 4C). Together, these results show 
that the combination of crizotinib and an mTOR inhibitor 
can be used both safely and effectively in human NB 
models.
Inhibition of ALK and mTOR signaling leads 
to  attenuation  of  tumor  growth  and  extends 
survival in a metastatic model of ALKF1174L/MYCN 
–amplified NB
Given the potency of crizotinib plus Torin2 against 
subcutaneous xenografted NB tumors, we asked if the 
combination would be effective in models of metastatic 
ALKF1174L/MYCN-positive NB. Six-week-old NSG mice 
were injected with luciferase-expressing Kelly cells by 
Figure 5: Combination of crizotinib and a dual PI3K/mTOR inhibitor results in synergistic activity in MYCN-non-
amplified cells. A, Survival analysis of SH-SY5Y (top) and CHLA-20 (bottom) cells treated for 3 days with increasing concentrations 
of crizotinib (x-axis), Torin2 (1 nM to 1 µM), or the combination at the indicated ratios (crizotinib:Torin2). B, Western blot analysis of 
the indicated proteins in SH-SY5Y (left) and CHLA-20 (right) cells treated at synergistic doses with either vehicle (DMSO), crizotinib 
(1-3 µM), Torin2 (100 nM), or the combination of crizotinib with the indicated inhibitor for 24 hr. C, Cell survival analysis of SH-SY5Y 
(top) and CHLA-20 (bottom) cells treated with increasing concentrations of crizotinib (x-axis), PF-05212384 (PF-052, 0.1 nM to 6 µM), 
or the combination at the indicated ratios (crizotinib:PF-05212384) for 3 days. D, Western blot analysis of the indicated proteins in SH-
SY5Y (left) and CHLA-20 (right) cells treated with either vehicle (DMSO), crizotinib (1 µM), PF-05212384 (5 µM) or the combination of 
crizotinib with the indicated inhibitor for 24 hr.Oncotarget 8744 www.impactjournals.com/oncotarget
lateral tail vein injection, with bioluminescence used to 
assess engraftment in the liver 6 days later. At 10 days 
post injection, repeat imaging revealed increased tumor 
burden with metastases to many organs, including bone 
marrow and lungs, reminiscent of human stage 4 NB. At 
this point, mice were divided into four treatment groups 
based on similar mean bioluminescence intensities (n = 8 
per group) and received vehicle, crizotinib (100 mg/kg), 
Torin2 (20 mg/kg), or a combination of these agents, given 
in daily oral doses for 10 consecutive days. The standard 
dose of crizotinib (100 mg/kg) allowed us to determine its 
tolerability in combination with other agents. Mice treated 
with the combination of crizotinib and Torin2 showed 
signs of toxicity after 6 days of treatment, but these effects 
resolved rapidly after cessation of treatment for 6 days, at 
which point the combination was restarted and continued 
in 5-day on/off cycles as described for the s.c. models. 
Serial monitoring of tumors by bioluminescence did not 
reveal any significant differences among the treatment 
groups until day 21, at which time the cohort treated 
with crizotinib plus Torin2 had lower bioluminescence 
compared to mice treated with single agents or vehicle 
(Fig. 4E and Supplementary Fig. S2C). As in the s.c. 
models, monotherapy with crizotinib or Torin2 did not 
appreciably affect the tumor burden or survival in our 
metastatic model, in contrast to combination therapy, 
which resulted in significant suppression of tumor growth 
and prolongation of survival (Fig. 4F). These in vivo data 
support the use of crizotinib with an mTOR catalytic 
inhibitor in patients with ALKF1174L-mutated,  MYCN-
amplified tumors. 
The combination of crizotinib and a dual PI3K/
mTOR inhibitor is required to induce cytotoxicity 
in  ALKF1174L-positive  NB  cells  without  MYCN 
amplification
We next determined whether the combination of 
crizotinib and Torin2 would be as effective in ALKF1174L-
expressing SH-SY5Y without MYCN amplification (Fig. 
5A and 5B). In contrast to the single agent crizotinib 
response in MYCN amplified cells (Fig. 1 and Fig. 3C), 
cells with absent MYCN  amplification  demonstrated 
reduced  pRPS6  and  p4E-BP1  expression  (Fig.  5B 
and 5D), which is consistent with the hypothesis that 
MYCN  activity  contributes  to  mTORC1  activation. 
In these cells, the combination of Torin2 and crizotinib 
led to a decrease in mTORC1 and mTORC2 signaling 
as evidenced by downregulated pRPS6, p4E-BP1 and 
pAKT473, respectively (Fig. 5B). However, this was not 
reflected in synergistic or additive cytotoxicity (Fig. 5A), 
most likely due to loss of feedback inhibition and the 
marked reactivation of pAKTT308 (Fig. 5B). These data 
suggested the need for an inhibitor that was also active 
against  PI3K.  Hence,  we  tested  PF-05212384,  which 
is extremely potent against both PI3K and mTOR (IC50 
of 0.4 and 1.6 nM, respectively). When combined with 
crizotinib, this compound showed synergistic activity in 
these cells (Fig. 5C and 5D), leading to the downregulation 
of not only mTORC1 and mTORC2, but also PI3K (Fig. 
5D). We further validated these findings in CHLA-20 
cells that express the more common R1275Q mutation, 
suggesting that various ALK mutations respond similarly 
to the combination in the setting of non-amplified MYCN. 
These findings suggest that mutant ALK-expressing NB 
cells with non-amplified MYCN may respond better to an 
inhibitor that is equally potent against mTOR and PI3K 
when combined with crizotinib.
DISCUSSION
The ALKF1174L mutation, which occurs in NB and 
cosegregates with the MYCN oncogene, demonstrates 
limited susceptibility to crizotinib both in animal models 
and in clinical testing [4, 6]. We have previously shown 
that the combination of crizotinib with an mTOR inhibitor 
induces responses in transgenic mouse models of NB 
positive for ALKF1174L and amplified MYCN [6]. Here, we 
provide a molecular basis for this effect, demonstrating 
that incomplete inhibition of mTORC1 limits the activity 
of crizotinib in NB cells that express both ALKF1174L and 
deregulated MYCN. This interpretation is supported by our 
observation that concomitant inhibition of mTOR restores 
sensitivity to crizotinib in NB models. We also show that 
this combination is not as effective in ALK-mutated cells 
expressing non-amplified MYCN. In such cells, an agent 
with appreciable activity against PI3K as well as mTOR 
was most effective when combined with crizotinib.
In  cells  expressing  ALKF1174L  and  amplified 
MYCN, crizotinib treatment had minimal to no effect 
on pRPS6 activity, suggesting that MYCN was capable 
of maintaining mTORC1 activity in this context. This 
prediction  was  confirmed  in  MYCN-repressible SHEP 
NB cells, where overexpression of MYCN in the presence 
of constitutively activated ALKF1174L led to sustained 
activation  of  pRPS6.  Moreover,  repression  or  shRNA 
knockdown of MYCN led to diminished activation of 
mTORC1 targets. In cells expressing mutant ALK and 
wild-type  MYCN, moreover, exposure to crizotinib 
resulted in downregulation of pRPS6 activity, in contrast 
to MYCN-amplified cells where pRPS6 was unaffected, 
again emphasizing the contribution of deregulated MYCN 
to the sustained activation of mTORC1. Thus, persistence 
of mTORC1 in the presence of amplified MYCN may 
be a general phenomenon in ALKF1174L-mutated, MYCN-
amplified  NB  tumors,  especially  since  this  mutation 
segregates with MYCN amplification [7]. Moreover, it 
is likely that in these cells, even newer ALK inhibitors 
with higher potency against the mutant kinase, will be 
limited by persistent activity of deregulated MYCN. We 
also observed that in cells in which MYCN expression had Oncotarget 8745 www.impactjournals.com/oncotarget
been abrogated, pAKTT308 was upregulated. This reciprocal 
relationship illustrates the relief of feedback inhibition by 
mTORC1 and appears to occur not only in NB but in other 
cancers as well [18, 19]. Such loss of feedback inhibition 
has also been shown to activate upstream RTKs [13] thus 
questioning the use of downstream signaling inhibitors as 
single agents to secure a sustained response. 
The ability of MYCN to sustain mTORC1 activity 
is consistent with previous reports showing that MYC 
overexpression or deregulation activates mTOR signaling 
[20].  Indeed,  MYC  amplification  has  been  observed 
more often in cells resistant to PI3K/mTOR inhibitors, 
as illustrated by the elevated expression of MYC and 
eIF4E in cells that have acquired resistance to the mTOR 
inhibitor BEZ235 [21]. The exact mechanism by which 
MYCN activates mTORC1 is unclear, but may entail 
the repression of AMP-activated protein kinase (AMPK) 
signaling [22] or transcriptional regulation of the 
negative mTORC1 regulator TSC2 [23]. As previously 
shown, tumors with high levels of MYCN respond 
quite dramatically to mTORC1 inhibition, although this 
property alone does not appear to be sufficient in tumors 
expressing ALKF1174L as well [6].
Figure 6 shows the impact of the ALKF1174L 
mutation on PI3K/AKT/mTOR signaling in NB, and the 
opportunities these interactions afford for targeted therapy. 
Cells expressing mutant ALK rely on phosphorylation 
of  AKT  at  T308  and  S473  via  ALK-activated  PI3K 
and  mTORC2,  respectively,  for  growth  and  survival. 
Subsequent  activation  of  mTORC1  and  RPS6  leads 
to inhibition of PI3K, creating a feedback loop that is 
needed for fine-tuning of this survival mechanism (Fig. 
6A). In this context, crizotinib by itself only marginally 
reduces the activities of PI3K and mTORC2 (Fig. 6B). 
In  cells  expressing  both  the  ALKF1174L  mutation and 
amplified  MYCN,  mTORC1  activity  is  maintained  by 
deregulated MYCN (Fig. 6B). Here the addition of 
an mTOR inhibitor such as Torin2 (or any equivalent 
clinically available agent) results in a synergistic response 
in which the downregulation of mTORC1 complements 
the crizotinib-driven inhibition of ALK to suppress PI3K/
AKT activity (Fig. 6D). In cells expressing mutant ALK 
Figure 6: Model for combined use of crizotinib and mTOR inhibitors in ALKF1174L-mutated NB cells with MYCN 
amplification. A, In ALKF1174L-mutant NB cells, AKT is phosphorylated at T308 and S473 by ALK-activated PI3K and mTORC2, 
respectively,  promoting  cell  survival,  transcriptional  activation  through  release  of  4E-BP1  from  eIF4,  and  ribosome  biogenesis 
through activation of RPS6. Activation of RPS6 in turn leads to inhibition of PI3K, creating a feedback loop that permits fine-tuning 
of proliferative and survival signaling. In MYCN-amplified, ALKF1174L-mutated NB cells, MYCN drives cellular proliferation, leading to 
increased dependence on RPS6 and 4E-BP1 activity. B, Treatment of these cells with crizotinib as a single agent inadequately inhibits 
mutant ALK, leading to marginally reduced PI3K (pAKTT308) and mTORC2 (pAKTS473) activities and a modest reduction in cell survival. 
Although the reduction in pAKT levels leads to a minimal reduction of pRPS6 in MYCN-amplified cells, this response is not sustained, as 
deregulated MYCN maintains upregulated mTORC1 activity. C, Single-agent treatment with specific ATP-competitive mTOR inhibitors, 
such as Torin2, blocks both mTORC1 and mTORC2 activity, downregulating pRPS6 and pAKTS473, although amplified MYCN continues 
to promote persistent mTORC1 activation and some level of PI3K feedback inhibition. D, The combination of crizotinib and Torin2 in 
MYCN-amplified cells targets the activities of PI3K, mTORC1 and mTORC2 simultaneously; continued loss of feedback inhibition of 
PI3K activity via incomplete suppression of MYCN/mTORC1/RPS6 signaling synergizes with crizotinib-driven inhibition of ALK to 
downregulate PI3K activity and, in turn, AKTT308 phosphorylation.Oncotarget 8746 www.impactjournals.com/oncotarget
without deregulated MYCN, the picture is less clear. 
Exclusive use of Torin2, although able to completely 
downregulate  mTORC1  activity  in  the  absence  of 
MYCN, leads to a much more striking increase of AKT 
phosphorylation by PI3K. Such loss of feedback inhibition 
leading to reciprocal activation of upstream signaling is a 
major limitation of single-agent kinase inhibitor therapy 
and suggests that a better result would be obtained by 
combining crizotinib with an inhibitor that possesses 
potent activity against PI3K as well as mTOR.
Although downstream signaling in cancer cells 
depends  largely  on  the  specific  cell  type,  mTORC1 
activation is a prominent feature of a number of different 
cancers that develop resistance to upstream kinase 
inhibitors [24, 25]. In PIK3CA-mutant breast cancer cells, 
for example, high levels of residual pRPS6 after treatment 
with a specific PI3K inhibitor positively correlate with 
either intrinsic or acquired resistance to this agent, which 
can  be  reversed  by  addition  of  a  specific  mTORC1 
inhibitor  [24].  Similarly,  mTORC1  activation  predicts 
responsiveness  to  RAF  or  MEK  inhibitors  in  BRAF-
mutant melanoma; in tumors that do not respond, pRPS6 
remains activated and combining mTORC1 inhibition with 
RAF or MEK inhibition induces a cytotoxic response [25]. 
These observations, together with our findings in NB cells, 
support aberrant activation of PI3K/mTOR as part of a 
mechanism of acquired and/or innate resistance to kinase 
inhibitors and raise the possibility of adding PI3K/mTOR 
inhibitors to upstream kinase inhibitors at the outset of 
therapy. 
It  is  becoming  increasingly  clear  that  efforts  to 
perturb the signaling networks in a tumor cell using 
a single upstream inhibitor are likely to be futile. Our 
data suggest a need for clinical trials of ALK inhibitors 
in combination with downstream pathway inhibitors to 
enhance the antitumor activity of the former compounds, 
in particular, their ability to overcome the resistance of 
ALKF1174L–mutated NB cells to crizotinib. The strategies 
described  here  could  also  benefit  patients  with  ALK-
translocated cancers, where the F1174L mutation 
modulates crizotinib resistance and the same signaling 
pathways that drive tumor cells without translocated 
ALK are active. Finally, such strategies may be useful in 
delaying or even forestalling the development of resistance 
to newer ALK inhibitors.
MATERIALS AND METHODS 
Cell lines and inhibitors
Neuroblastoma cell lines were obtained from the 
ATCC, ECACC, or the Children’s Oncology Group 
(COG). Kelly, LAN-1, NGP, SHEP, and SH-SY5Y 
human NB cells [2] were cultured in RPMI-1640 medium 
supplemented with 10% fetal bovine serum (FBS), 
100 units/mL penicillin, and 100 µg/mL streptomycin. 
CHLA-20 human NB cells were cultured in IMDM media 
supplemented with 20% FBS, 100 units/mL penicillin, 
100  µg/mL  streptomycin,  and  1X  Insulin-Transferrin-
Selenium (Gibco). Cell lines were routinely mycoplasma-
tested and genotyped at the DFCI Core Facility. Crizotinib 
(PF-02341066) and PF-05212384 were obtained from 
Pfizer Inc. (New York, NY) through a materials transfer 
agreement. Torin1 and Torin2 were synthesized in Dr. 
Nathanael Gray’s laboratory. Rapamycin, NVP-BEZ235, 
AZD8055, LY294002, and GDC-0941 were purchased 
from Selleckchem.com (Houston, TX).
Gene expression and gene set enrichment analyses 
(GSEA)
RNA was extracted with TRIzol® reagent according 
to the manufacturer’s protocol (Invitrogen) from Kelly 
NB cells treated in triplicate with either vehicle (DMSO) 
or crizotinib (4 µM) for 6 hours. Gene expression was 
evaluated using Affymetrix U133A DNA microarrays 
(Affymetrix Inc. Santa Clara, CA). Data analysis was 
performed with GenePattern software [26] and GSEA as 
described previously [27].
Cell viability assay and drug combination analysis
Viability experiments were performed in triplicate 
in 96-well plates and repeated at least three times with 
the  Cell  Proliferation  Kit  I  (Roche)  or  CellTiter-Glo 
Luminescent cell viability assay (Promega, Madison, 
WI), according to the manufacturer’s instructions. The 
synergy/additivity analyses were performed in 384- or 96-
well plate format in two to four replicates and viability 
measured using the CellTiter-Glo viability assay as per 
the manufacturer’s protocol. Compounds were added 
simultaneously at the indicated fixed ratios, and synergy 
was assessed using Calcusyn software (Biosoft, Ferguson, 
MO), using the Chou-Talalay method [28]. The resulting 
concentration pairs at the indicated ratios were visualized 
using Prism (GraphPad Software) or by isobologram 
(Microsoft Xcel) [29].
Immunoblotting
Cell lysis and immunoblotting were performed as 
previously described [2]. All proteins were detected by 
chemiluminescence. Antibodies for pALKY1604 (3341), 
ALK (3333), pAKTS473 (9271), pAKTT308 (4056), AKT 
(9272), pRPS6S240/244 (2215), RPS6 (2217), MYCN (9405), 
GAPDH  (2118),  β-Actin  (4967),  β-Tubulin  (2128), 
4E-BP1 (9644), p4E-BP1T37/46  (9459),  mTOR  (2972), 
pmTORS2448 (2971) and PARP (9542) were purchased from Oncotarget 8747 www.impactjournals.com/oncotarget
Cell Signaling Technologies. Densitometry was performed 
using  the  ImageJ  software  package  and  statistical 
significance calculated using GraphPad Prism.
Plasmid transfections 
The oligos for ALK shRNA #6 were synthesized 
as previously described [30], while those for shRNA #8 
were designed using the program described in [31]. Oligos 
were cloned into the pLKO-1 lentiviral vector containing 
the ampicillin resistance cassette. MYCN  shRNA 
constructs were purchased from the Broad Institute (#1-
TRCN0000020694, #3-TRCN0000363425). The shRNA 
knockdown experiments were performed as previously 
described [2]. The ALKF1174L mutation was introduced 
into wild type ALK  cDNA  using  the  QuickChange  II 
Site-Directed Mutagenesis Kit (Strata-gene), cloned into 
the MSCV vector backbone containing the puromycin 
selectable marker (Addgene), and transfected into 293T 
cells with helper plasmids for virus production. SHEP 
cells were transduced with ALKF1174L–positive retrovirus, 
followed by puromycin selection for at least 3 days. 
MYCN expression in SHEP cells was repressed with 1µg/
ml doxycycline for 24 hr. For the in vivo studies, Kelly 
cells were transduced with virus containing the Luc-
mCherry-puro plasmid as described above.
Cell cycle and Annexin V analysis
Kelly cells were treated for 72 hrs. with synergistic/
additive doses of crizotinib (200 nM), Torin2 (20 nM), or 
the combination and cell cycle analyses were performed as 
previously described [2] or Annexin V staining performed 
using the BD Pharmingen FITC Annexin V Apoptosis 
Detection Kit I according to manufacturer’s protocol.
Immunohistochemistry
Tumors from the subcutaneous xenograft model 
were harvested at sacrifice, fixed in 10% neutral buffered 
formalin and paraffin-embedded for histologic studies. 
Tissue sections were stained with hematoxylin and eosin 
for morphological analysis as previously described [6]. 
For immunohistochemistry, 5-µm sections were stained 
with  antibodies  to  ALK  (Ventana),  pRPS6S240/244, and 
cleaved caspase 3 (Cell Signaling Technologies: 2215 and 
9664, respectively) using standard methods, including 
heat-induced epitope retrieval with citrate buffer pH 6 for 
pRPS6S240/244 and cleaved caspase 3 or EDTA buffer for 
ALK.
Xenograft studies 
All animal experiments were performed following 
approval  from  the  Institutional Animal  Care  and  Use 
Committee of the DFCI. NSG (Nod scid gamma) mice 
were used for the in vivo tumor growth inhibition studies.
Subcutaneous model. Animals were injected with 5 
x 106 Kelly cells and monitored until tumors appeared. 
Tumor volumes were calculated using the spheroid 
formula. Mice were divided into four treatment groups 
with similar mean tumor volumes (~60 mm3, n=8 per 
group) and treated with vehicle, crizotinib (75 mg/kg) p. 
o. daily, Torin2 (20 mg/kg) p. o. daily, or a combination 
of the two compounds. Treatments were administered in 5 
day “cycles”, each consisting of 5 days on and 5 days off, 
for a total of three cycles. Tumors were measured at least 
once weekly and mice were sacrificed when tumor volume 
reached 1500 mm3. Tumors were collected from three 
mice per group as they reached the volume threshold; 
half of the specimens were fixed in 10% neutral-buffered 
formalin, while the other half were snap frozen in liquid 
nitrogen.
Metastatic model. Fifty 6-week-old NSG mice were 
injected in the lateral tail vein with 5 x 106 Kelly-Luc-
mCherry-puro cells. Six days after injection, 3 randomly 
selected cages of mice were imaged to determine baseline 
tumor burden. Ten days after injection, all mice were 
imaged and divided into four treatment groups (8 animals/
group) with similar mean bioluminescence intensities: 
vehicle (nuclease-free water, Ambion, AM9916), crizotinib 
at 100 mg/kg, Torin2 at 20 mg/kg, or the crizotinib/Torin2 
combination. Single agent crizotinib and Torin2 were 
given orally once daily for 10 consecutive days. Mice 
receiving the combination were treated orally once daily 
for 6 days, with treatment then adjusted to 5-day on/off 
cycles, (days 1-6, 13-17, and 23-27) to avoid toxicity. 
Tumor burden and mouse weights were monitored every 
3-5 days by bioluminescence as previously described [32].
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